Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
History, Art, Technology & Companies
Explore the main themes, entities and connections around BioNTech. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
company vaccine mrna-based covid-19 cancer mrna pfizer development research million 2020 vaccines manufacturing diseases germany 2026 us biontech's 2019 also
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| BioNTech | Area served | Worldwide | 1.00 | infobox |
| BioNTech | Founded | 2008; 18 years ago (2008) | 1.00 | infobox |
| BioNTech | Founders | Uğur Şahin | 1.00 | infobox |
| BioNTech | Founders | Özlem Türeci | 1.00 | infobox |
| BioNTech | Founders | Christoph Huber | 1.00 | infobox |
| BioNTech | Headquarters | Mainz, Germany | 1.00 | infobox |
| BioNTech | Industry | Biotechnology | 1.00 | infobox |
| BioNTech | ISIN | US09075V1026 | 1.00 | infobox |
| BioNTech | Key people | Uğur Şahin (CEO) | 1.00 | infobox |
| BioNTech | Key people | Annemarie Hanekamp (CCO) | 1.00 | infobox |
| BioNTech | Key people | Kylie Jimenez (CPO) | 1.00 | infobox |
| BioNTech | Key people | Sierk Pötting (COO) | 1.00 | infobox |
| BioNTech | Key people | James Ryan (CLO, CBO) | 1.00 | infobox |
| BioNTech | Key people | Özlem Türeci (CMO) | 1.00 | infobox |
| BioNTech | Key people | Ramón Zapata (CFO) | 1.00 | infobox |
| BioNTech | Net income | €−1.14 billion (2025) | 1.00 | infobox |
| BioNTech | Number of employees | 7,807 (2025) | 1.00 | infobox |
| BioNTech | Number of locations | 26 (2026) | 1.00 | infobox |
| BioNTech | Operating income | €−1.40 billion (2025) | 1.00 | infobox |
| BioNTech | Products | Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates | 1.00 | infobox |
| BioNTech | Revenue | €2.87 billion (2025) | 1.00 | infobox |
| BioNTech | Services | Immunotherapy | 1.00 | infobox |
| BioNTech | Total assets | €21.99 billion (2025) | 1.00 | infobox |
| BioNTech | Total equity | €19.22 billion (2025) | 1.00 | infobox |
| BioNTech | Traded as | Nasdaq: BNTX | 1.00 | infobox |
| BioNTech | Type | Public company | 1.00 | infobox |
| BioNTech | Website | biontech.com | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.